FDA approval positions Titan Prime as Coloplast’s updated IPP option for men with severe erectile dysfunction seeking long-term prosthetic restoration of erectile function. Improved flaccid ...
Dose escalation to 10 MBq produced no DLTs and no MTD, with grade ≥3 TRAEs in 11%–24% and rare AE-driven discontinuations. Xerostomia occurred in approximately 90% to 97% of patients, remained grade 1 ...
Praful Ravi, MB, BChir, MRCP, discusses results from PSMAtrack, which assessed changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer. According to Ravi, ...
Pedro C. Barata, MD, MSc, FACP, discusses preliminary findings from the phase 3 ProstACT Global study evaluating 177Lu-rosopatamab plus standard of care for patients with mCRPC. According to Barata, ...
ctDNA-guided adjuvant atezolizumab for MIBC achieved improved DFS and OS versus placebo in ctDNA-positive patients, enabled by FDA-approved Signatera CDx companion diagnostic. Durvalumab plus BCG ...
In this episode of Pearls & Perspectives, Amy Pearlman, MD, speaks with Tom Riester of LTR Pharma about the development of a novel intranasal therapy for erectile dysfunction, exploring its potential ...
In “Perioperative Therapy Expansion in Cisplatin-Ineligible MIBC,” our panel explores how the treatment paradigm for muscle-invasive bladder cancer (MIBC) is rapidly evolving with the emergence of ...
OAB is a chronic, potentially debilitating condition affecting a substantial proportion of patients in urologic practice, and effective long-term management depends on systematic escalation from ...
The FDA approved cefepime and zidebactam for adult complicated UTI after ENHANCE-1 showed an 89.0% response rate at test of cure. The FDA has approved cefepime and zidebactam (ZAYNICH) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results